Description
What is Arimidex?
Arimidex is the brand name for Anastrozole, which is a substance used for the treatment of breast cancer for women after menopause. However, the drug has also found its way to the bodybuilding world, where it helps bodybuilders achieve certain results and improve their performance.
What does Arimidex do?
Arimidex successfully lowers the estrogen found in the body, turning into an efficient solution for bodybuilders who are looking to decrease the side effects of anabolic steroids. It does so by preventing aromatase from properly functioning in the body. Aromatase is an enzyme responsible for creating estrogen using steroid hormones like testosterone. By stopping aromatase, the drug limits estrogen levels in the body.
What is the recommended Arimidex dosage?
The standard Arimidex dosage recommended for bodybuilders is 0.5 mg twice a week beginning from week two of the anabolic steroid cycle. The drug is taken orally and the dose may vary based on your level of experience.
Improve Your Performance With Anastrozole
What is Anastrozole used for?
As a result of anabolic steroid intake for muscle growth and better performance, males may develop breasts as estrogen levels in the body start to increase. Arimidex or Anastrozole helps in keeping estrogen levels low and therefore omits the risk of breast growth in men. Anastrozole for bodybuilding may not be the original reason for the creation of the drug but is nowadays a popular solution for men looking to grow muscle mass and improve their overall performance.
Before you buy Anastrozole, it’s advisable to get as much information on the substance as possible and schedule a consultation with an expert with a medical background and experience. Keep in mind that the drug is only approved by the Food and Drug Administration for the purpose of breast cancer treatment. Despite its positive effects for bodybuilders looking to prevent high estrogen levels in the body, it’s not a recommended drug in the bodybuilder world.
Reviews
There are no reviews yet.